Adjuvant Chemotherapy and Prognostic Factors in Stage II Colon Cancer - Izmir Oncology Group Study |
Kucukzeybek, Yuksel
(Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital)
Dirican, Ahmet (Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) Demir, Lutfiye (Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) Yildirim, Serkan (Department of Internal Medicine, Izmir Bozyaka Training and Research Hospital) Akyol, Murat (Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) Yildiz, Yasar (Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) Bayoglu, Ibrahim Vedat (Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) Alacacioglu, Ahmet (Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) Varol, Umut (Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) Salman, Tarik (Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) Yildiz, Ibrahim (Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) Can, Huseyin (Department of Family Medicine, Izmir Katip Celebi University Ataturk Training and Research Hospital) Tarhan, Mustafa Oktay (Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) |
1 | Labianca R, Nordlinger B, Beretta GD, et al (2013). Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 24, 64-72. |
2 | Lai JH, Zhou YJ, Bin D, Qiangchen, Wang SY (2014). Clinical significance of detecting lymphatic and blood vessel invasion in stage II colon cancer using markers D2-40 and CD34 in combination. Asia Pac J Cancer Prev, 15, 1363-70. DOI |
3 | Meng J, Lu XB, Tang YX, et al (2013). Effects of allogeneic blood transfusion in patients with stage II colon cancer. Asia Pac J Cancer Prev, 14, 347-50. DOI ScienceOn |
4 | Moertel CG, Fleming TR, Macdonald JS, et al (1990). Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med, 322, 352-8. DOI |
5 | O'Connor ES, Greenblatt DY, LoConte NK, et al (2011). Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol, 29, 3381-8. DOI |
6 | Ozdemir Y, Akin ML, Sucullu I, Balta AZ, Yucel E (2014). Pretreatment neutrophil/lymphocyte ratio as a prognostic aid in colorectal cancer. Asia Pac J Cancer Prev, 15, 2647-50. DOI ScienceOn |
7 | Quah HM, Chou JF, Gonen M, et al (2008). Identification of patients with high-risk stage II colon cancer for adjuvant therapy. Dis Colon Rectum, 51, 503-7. DOI |
8 | Ribic CM, Sargent DJ, Moore MJ, et al (2003). Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med, 349, 247-57. DOI |
9 | Sargent DJ, Marsoni S, Monges G, et al (2010). Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol, 28, 3219-26. DOI ScienceOn |
10 | Siegel R, Desantis C, Jemal A,(2014). Colorectal cancer statistics, 2014. CA Cancer J Clin, 64, 104-17. DOI ScienceOn |
11 | Talaiezadeh A, Tabesh H, Sattari A, Ebrahimi S (2013). Cancer incidence of southwest of Iran: first report from Khuzestan population-based cancer registry, 2002-2009. Asia Pac J Cancer Prev, 14, 7517-22. DOI ScienceOn |
12 | Tournigand C, Andre T, Bonnetain F, et al (2012). Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the multicenter international study of oxaliplatin, fluorouracil, and leucovorin in the adjuvant treatment of colon cancer trial. J Clin Oncol, 30, 3353-60. DOI |
13 | Trivedi H, Chamarthy U, Dicarlo L, Herman J, Srkalovic G (2014). Prognostic factors of overall survivall for patients with stage II colon cancer. Acta Med Acad, 43, 134-43. DOI |
14 | Wilkinson NW, Yothers G, Lopa S, et al (2010). Long-term survival results of surgery alone versus surgery plus 5fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modernadjuvant trials. Ann Surg Oncol, 17, 959-66. DOI |
15 | Wu X, Zhang J, He X, et al (2012). Postoperative adjuvant chemotherapy for stage II colorectal cancer: a systematic review of 12 randomized controlled trials. J Gastrointest Surg, 16, 646-55. DOI |
16 | Yothers G, O'Connell MJ, Allegra CJ, et al (2011). Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol, 29, 3768-74. DOI |
17 | Baghestani AR, Daneshvar T, Pourhoseingholi MA, Asadzade H (2014). Survival of colorectal cancer patients in the presence of competing-risk. Asia Pac J Cancer Prev, 15, 6253-5. DOI |
18 | Andre T, Boni C, Mounedji-Boudiaf L, et al (2004). Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med, 350, 2343-51. DOI |
19 | Artac M, Turhal NS, Kocer M, et al (2014). Do high risk features support the use of adjuvant chemotherapy in stage II colon cancer? a turkish oncology group study. Tumori, 100, 143-8. |
20 | Baek JY, Yeo HY, Chang HJ, et al (2014). Serpin B5 is a CEA interacting biomarker for colorectal cancer. Int J Cancer, 134, 1595-604. DOI |
21 | Benson AB 3rd, Schrag D, Somerfield MR, et al (2004). American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol, 22, 3408-19. DOI |
22 | Compton CC, Fielding LP, Burgart LJ, et al (2000). Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med, 124, 979-94. |
23 | Cakar B, Varol U, Junushova B, et al (2013). Evaluation of the efficacy of adjuvant chemotherapy in patients with high risk stage II colon cancer. JBUON, 18, 372-376. |
24 | Chang GJ, Rodriguez-Bigas MA, Skibber JM, et al (2007). Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst, 99, 433-41. DOI |
25 | Chen HS, Sheen-Chen SM, (2000). Obstruction and perforation in colorectal adenocarcinoma: an analysis of prognosis and current trends. Surgery, 127, 370-6. DOI |
26 | Eisenberg B, Decosse JJ, Harford F, et al (1982). Carcinoma of the colon and rectum: the natural history reviewed in 1704 patients. Cancer, 49, 1131-4. DOI |
27 | Ferlay J, Shin HR, Bray F, et al (2008). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917. |
28 | Gill S, Loprinzi CL, Sargent DJ, et al (2004). Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol, 22, 1797-806. DOI |
29 | Gray R, Barnwell J, McConkey C, et al (2007) Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet, 370, 2020-9. DOI |
30 | Kuebler JP, Wieand HS, O'Connell MJ, et al (2007). Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol, 25, 2198-204. DOI |